---
title: "Kairos Pharma Shareholders Approve Reverse Split, Governance Measures"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291344261.md"
description: "Kairos Pharma shareholders approved a reverse stock split (1:3 to 1:250), elected four directors, and ratified Weinberg & Company as auditor. They also endorsed executive compensation and expanded the Equity Incentive Plan by 5 million shares with an evergreen provision. The company, focused on oncology therapies, currently has a market cap of $7.49M and a 'Buy' analyst rating with a $12 price target."
datetime: "2026-06-30T21:50:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291344261.md)
  - [en](https://longbridge.com/en/news/291344261.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291344261.md)
generator: "portal-rs"
---

# Kairos Pharma Shareholders Approve Reverse Split, Governance Measures

Kairos Pharma, Ltd. ( (KAPA) ) has provided an update.

On June 29, 2026, Kairos Pharma Ltd. held its 2026 annual meeting of stockholders, where shareholders elected four directors to one-year terms and ratified Weinberg & Company, P.A. as the independent auditor for the fiscal year ending December 31, 2026. The meeting recorded participation from 62.81% of eligible shares, providing strong shareholder backing for the company’s governance and oversight framework.

Stockholders also approved an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1:3 and 1:250, to be implemented at the board’s discretion, signaling potential steps to manage share price and capital structure. In addition, shareholders endorsed executive compensation and expanded the 2023 Equity Incentive Plan by adding 5,000,000 shares and an evergreen provision for automatic 5% annual increases over ten years, reinforcing management incentives and long-term alignment with investor interests.

The most recent analyst rating on (KAPA) stock is a Buy  
 with a $12.00 price target.  
 To see the full list of analyst forecasts on Kairos Pharma, Ltd. stock,  
 see the KAPA Stock Forecast page. 

**More about Kairos Pharma, Ltd.**

Kairos Pharma Ltd. is a biopharmaceutical company focused on developing oncology therapies and related drug candidates. The company operates in the life sciences sector, targeting cancer treatment markets through clinical-stage research and development activities supported by public equity financing.

**Average Trading Volume:** 134,117

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $7.49M

### Related Stocks

- [KAPA.US](https://longbridge.com/en/quote/KAPA.US.md)

## Related News & Research

- [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md)
- [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md)
- [Zealand Pharma (CPSE:ZEAL) Reports Weaker Earnings, Is It Still Below Fair Value?](https://longbridge.com/en/news/297245804.md)
- [LSL Pharma Group Inc. reports Q2 results](https://longbridge.com/en/news/296953883.md)
- [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**